LSE - Delayed Quote USD

iRhythm Technologies, Inc. (0A7L.L)

117.11 +4.56 (+4.05%)
At close: April 24 at 6:59 PM GMT+1
Key Events
Loading Chart for 0A7L.L
DELL
  • Previous Close 112.55
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 132.83
  • Volume 0
  • Avg. Volume 25
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) -4.22
  • Earnings Date May 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

www.irhythmtech.com

2,000

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0A7L.L

Performance Overview: 0A7L.L

Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0A7L.L
9.06%
MSCI WORLD
5.23%

1-Year Return

0A7L.L
0.00%
MSCI WORLD
18.44%

3-Year Return

0A7L.L
41.88%
MSCI WORLD
12.98%

5-Year Return

0A7L.L
--
MSCI WORLD
19.01%

Compare To: 0A7L.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0A7L.L

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -25.05%

  • Return on Assets (ttm)

    -13.93%

  • Return on Equity (ttm)

    -54.86%

  • Revenue (ttm)

    492.68M

  • Net Income Avi to Common (ttm)

    -123.41M

  • Diluted EPS (ttm)

    -4.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    133.76M

  • Total Debt/Equity (mrq)

    61.79%

  • Levered Free Cash Flow (ttm)

    -10.02M

Company Insights: 0A7L.L